Bicara Therapeutics Inc [BCAX] stock is trading at $17.43, down -2.90%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCAX shares have gain 8.19% over the last week, with a monthly amount drifted -8.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicara Therapeutics Inc [NASDAQ: BCAX] stock has seen the most recent analyst activity on January 08, 2026, when BTIG Research initiated its Buy rating and assigned the stock a price target of $28. Previously, Mizuho started tracking the stock with Neutral rating on December 18, 2025, and set its price target to $18. On August 19, 2025, Piper Sandler initiated with an Overweight rating and assigned a price target of $36 on the stock. Wells Fargo upgraded its rating to a Equal Weight but stick to its price target of $8 on May 23, 2025. Wells Fargo initiated its recommendation with an Underweight and recommended $8 as its price target on April 17, 2025. Wedbush started tracking with an Outperform rating for this stock on February 06, 2025, and assigned it a price target of $31. In a note dated December 06, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $42 on this stock.
Bicara Therapeutics Inc [BCAX] stock has fluctuated between $7.80 and $19.71 over the past year. Currently, Wall Street analysts expect the stock to reach $28.67 within the next 12 months. Bicara Therapeutics Inc [NASDAQ: BCAX] shares were valued at $17.43 at the most recent close of the market. An investor can expect a potential return of 64.49% based on the average BCAX price forecast.
Analyzing the BCAX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.27 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Bicara Therapeutics Inc’s Current Ratio is 14.14. In addition, the Quick Ratio stands at 14.14 and the Cash Ratio stands at 8.16.
Transactions by insiders
Recent insider trading involved Hyep Ivan, Chief Financial Officer, that happened on Dec 22 ’25 when 9200.0 shares were sold. Officer, Hyep Ivan completed a deal on Dec 22 ’25 to buy 9200.0 shares. Meanwhile, President and COO Cohlhepp Ryan sold 12500.0 shares on Dec 15 ’25.
